Here's why the Estia Health Ltd IPO was overpriced

It's had a disastrous run so far, but could Estia Health Ltd (ASX:EHE) turn things around for investors?

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Quadrant Private Equity has been accused of exploiting investor interest in aged care after the disastrous sharemarket debut of Estia Health Ltd (ASX: EHE) last week.

Estia Health became the third aged-care operator to list on the ASX this year, following the successful floats of Japara Healthcare Ltd (ASX: JHC) and Regis Healthcare Ltd (ASX: REG). However, the stock fell more than 17% on its first day of trade and has since fallen a further 4% to be trading at $4.67. It has already lost nearly $200 million from its initial valuation.

In light of the stock's performance, Quadrant has been slammed for exploiting a market window created by the success of Japara and Regis with veteran investment banker David Kingston describing the float as over-priced and opportunistic, according to Fairfax media.

Indeed, the aged-care sector does offer enormous growth potential for investors. With Australia's growing and ageing population, the industry is expected to boom with the Aged and Community Services and Australia group even estimating that the country will need another 82,000 new aged care beds by 2020. Estia seems well placed to benefit, considering its string of acquisitions and its primary focus on acquiring single room facilities (which are the industry's most sought after).

However, Kingston has reportedly raised questions regarding Estia's ability to hit 2015 earnings forecasts, especially when compared to the forecasts of Regis, which he considers to be the best company of the three. As an example, while Regis owns almost 30% more beds, it has forecast an EBITDA margin of 20.3% for 2015-16, compared to Estia's higher forecast EBITDA margin of 23.7%.

Although Estia's shares are trading at a slight discount compared to Regis and Japara, investors should remain wary of the stock's actual worth and may wait until the release of Estia's first-half profit results (which are likely to be released in February) before buying the stock up again.

A much better bet than Estia Health

Motley Fool contributor Ryan Newman (@ASXvalueinvest) does not own shares in any of the companies mentioned.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »